๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
NCT06601335Head and Neck Squamous Cell Carcinoma
Akeso
Phase 3
510
Wuhan, Chengdu
2024-10-30
Active, closed
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
NCT06654297Esophageal Squamous Cell Carcinoma
West China Hospital
Phase 1
6
Chengdu
2024-10-27
Recruiting
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
NCT06558227Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
90
Chengdu
2024-10-24
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Active, closed
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier
Phase 3
57
Shenzhen, Chengdu, Beijing, Shanghai, Xi'an
2024-10-18
Active, closed
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
NCT06640049Neoplasms, Rectal
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Not yet open
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
NCT06645197Amyotrophic Lateral Sclerosis (ALS)
Peking University Third Hospital
Phase EARLY_PHASE1
7
Beijing, Fujian, Nanjing, Chengdu, Hangzhou
2024-10-16
Recruiting
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
NCT06664996Hepatocellular Carcinoma (HCC)
West China Hospital
Phase 2
33
Chengdu
2024-10-15
Not yet open
Phimumeยฎ Percutaneous Left Ventricular Assist System Study
NCT06639321Coronary Artery Disease
Shanghai NewMed Medical Co., Ltd.
Not applicable
250
Jilin City, Chengdu, Zhengzhou, Wuhan, Changsha, Shenyang
2024-10-14
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Active, closed
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
NCT06667050Gastric Adenocarcinoma
West China Hospital
Phase 2
58
Chengdu
2024-10-10
Active, closed
3-Dimensional Mapping System: The PULSTAR II Study
NCT07586176Atrial Fibrillation (Paroxysmal), Paroxysmal AF, Pulsed Field Ablation
Shanghai Shangyang Medical Technology Co., Ltd.
Not applicable
152
Chengdu
2024-10-10
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Nanning, Zhengzhou, Changchun, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
By invitation
The Effects and Mechanism of Parent Intervention for Autism Sprectrum Disorder
NCT07393893Autism Spectrum Disorder
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2024-10-08
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou
2024-10-04
Recruiting
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
NCT06742424Hepato Cellular Carcinoma (HCC)
West China Hospital
Phase 2
36
Chengdu
2024-10-01
Recruiting
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
NCT06675201Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
Sichuan University
Phase 2
165
Chengdu
2024-10-01
Not yet open
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
NCT06666153CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs
West China Hospital
Phase 1
27
Chengdu
2024-10
Not yet open
Twice-per-weekSelinexor, 2 Days Melphalan
NCT06613035Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Active, closed
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
NCT06635447Breast Cancer
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Active, closed
A Study in Patients With Myasthenia Gravis in China
NCT06700616Myasthenia Gravis
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Not yet open
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
NCT06616259Colorectal Cancer (CRC), Capecitabine, Cetuximab
Meng Qiu
Phase 3
452
Chengdu
2024-09-26
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xiโ€™an, Chengdu, Hangzhou, Huzhou
2024-09-21
Not yet open
The Effect of Aromatherapy for First Dental Visit Patients
NCT06598904Dental Anxiety
Sichuan University
Not applicable
120
Chengdu
2024-09-20
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Beijing, Chengdu, Shanghai
2024-09-19
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
By invitation
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
NCT06504043Hypercholesterolemia, Healthy Volunteers, LDL-Cholesterol
Hasten Biopharmaceutical Co., Ltd.
Phase 1
30
Chengdu
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation
NCT05556460Tricuspid Regurgitation
Hangzhou Valgen Medtech Co., Ltd
Not applicable
236
Chengdu, Hangzhou
2024-09-03
By invitation
A Integrated Study in Pediatric Patients with Cardiomyopathy
NCT06641830Pediatric Cardiomyopathy
West China Second University Hospital
Observational
800
Chengdu
2024-09-01
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, รœrรผmqi, Chongqing, Shanghai
2024-09-01
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
AI App for Management of Atopic Dermatitis
NCT06362629Atopic Dermatitis, Artificial Intelligence
West China Hospital
Not applicable
232
Chengdu
2024-09-01
By invitation
Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease
NCT06641843Kawasaki Disease, Cardiovascular Disease, Anomalous Origin of Coronary Artery
West China Second University Hospital
Observational
240
Chengdu
2024-09-01
Recruiting
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
NCT06787989Refractory Immune Cytopenia
iCell Gene Therapeutics
Phase 1
20
Chengdu
2024-08-31
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Recruiting
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
NCT06438822Cholangiocarcinoma
West China Hospital
Phase 2
51
Chengdu
2024-08-30
Recruiting
EASi-KIDNEYโ„ข (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jiazhuang, Jinan
2024-08-21
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
AbbVie
Phase 3
675
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Recruiting
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
NCT07122414Non-muscle Invasive Bladder Cancer (NMIBC)
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
80
Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu
2024-08-16
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Recruiting
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT06485466Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
Guohui Xu
Phase 3
101
Chengdu
2024-08-10
Recruiting
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
NCT06597201End Stage Renal Disease (ESRD)
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
A Study of Online Follow-up in Patients With Papillary Thyroid Cancer
NCT06800482Thyroid, Papillary Thyroid Cancer
West China Hospital
Not applicable
388
Chengdu
2024-08-07
Recruiting
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
NCT06484777Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
138
Chengdu
2024-08-07
Active, closed
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNฮฑ Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
Brii Biosciences Limited
Phase 2
150
Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-08-06
Recruiting
Identifying Local Field Potential Biomarkers for Obsessive-compulsive Disorder Treatment With Deep Brain Stimulation
NCT06542224Obsessive-Compulsive Disorder
West China Hospital
Not applicable
16
Chengdu, Zigong
2024-08-03
Recruiting
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
NCT06542094Major Depressive Disorder, Treatment Resistant Depression
West China Hospital
Not applicable
12
Chengdu
2024-08-03
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Active, closed
AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06508606Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 2
20
Chengdu
2024-08-01
Recruiting
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
NCT06532591NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2
20
Chengdu
2024-08-01
Not yet open
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
NCT06523049Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
Hao Zeng
Phase 2
67
Chengdu
2024-08
Recruiting
Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease
NCT06527768Chronic Kidney Diseases, Metabolic Syndrome
Chinese University of Hong Kong
Not applicable
40
Chengdu
2024-07-31
Recruiting
Clinical Trial of Pegylated Interferon ฮฑ-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .
NCT07008755HFMD
Zhengzhou Children's Hospital, China
Not applicable
90
Chengdu, Liangshan, Zhengzhou, Ziyang
2024-07-31
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Active, closed
Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
NCT06524947Acute Gastroenteropathy Due to Norovirus
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 3
6,600
Nanning, Changsha, Chengdu
2024-07-27
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
NCT06519552Mucopolysaccharidosis Type I
West China Hospital
Phase 1
6
Chengdu
2024-07-22
Recruiting
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
NCT06441812Eosinophilic Asthma Patients
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
200
Chengdu
2024-07-19
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
Peginterferon ฮฑ-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia
NCT06881056Respiratory Syncytial Virus (RSV)
West China Second University Hospital
Not applicable
90
Chengdu
2024-07-17
Recruiting
The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety of Mentor Breast Implants in Chinese Population
NCT06510205Breast Augmentation, Mammaplasty
Johnson & Johnson Medical (Shanghai) Ltd.
Observational
6,111
Chengdu, Kunming, Shenzhen
2024-07-14
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357Pemphigus
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Active, closed
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
NCT06465914Genital Wart, Penile Cancer, Anal Cancer, PIN-1
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3
9,000
Nanning, Changsha, Taiyuan, Chengdu, Kunming
2024-07-11
Active, closed
FIH of PFBalloon for PVI
NCT07320976Paroxysmal Atrial Fibrillation
The Third People's Hospital of Chengdu
Not applicable
35
Chengdu
2024-07-10
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
136
Guangzhou, Wuhan, Shang'ai, Shanghai, Chengdu, Hangzhou, Beijing
2024-07-09
Recruiting
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
NCT06390306Chronic Myeloid Leukemia
Peking University People's Hospital
Observational
30
Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo
2024-07-01
Recruiting
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06444009Head and Neck Squamous Cell Carcinoma
Lei Liu
Phase 2
90
Chengdu
2024-07-01
Recruiting
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597Generalized Myasthenia Gravis
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
NCT06446726Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2
30
Chengdu
2024-06-30
Recruiting
Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)
NCT06385379Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Recruiting
Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations
NCT06479343Intracranial Arteriovenous Malformations
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
170
Guangzhou, Zhengzhou, Nanjing, Changchun, Shenyang, Jinan, Beijing, Chengdu
2024-06-27
Recruiting
Titration of Inspired Oxygen to Decrease the Incidence of Postoperative Pulmonary Complications
NCT06243146Unrecognized Condition
Sichuan Provincial People's Hospital
Not applicable
156
Chengdu
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Active, closed
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
NCT06433531Generalized Pustular Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Recruiting
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257Asthma
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
Boehringer Ingelheim
Phase 3
6,000
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT05562947Neovascular Age-related Macular Degeneration, nAMD
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy
NCT06380842Necrotizing Pancreatitis
Chunling Jiang
Observational
200
Chengdu
2024-06-15
Recruiting
Nursing Interventions for Alzheimer's Patients During PET/CT Imaging
NCT06784830Alzheimer's Disease
Sichuan Provincial People's Hospital
Not applicable
200
Chengdu
2024-06-15
Recruiting
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
NCT06378242High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Rows per page Showing 701–800 of 1291
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=8

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.